Trial Profile

A Trial of Immunological Outcomes of Sublingual Immunotherapy for House Dust Mite (D. Pteronyssinus) Allergy

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs House dust mite allergy immunotherapy (Primary)
Indications Allergic asthma; Allergic rhinitis; Asthma; Hypersensitivity
Focus Pharmacodynamics

Most Recent Events

13 Feb 2013 Biomarkers information updated
15 Nov 2009 Results were published in the American Journal of Respiratory and Critical Care Medicine.
15 Nov 2009 Status changed from not yet recruiting to completed based on publication of results in the American Journal of Respiratory and Critical Care Medicine.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com